The status of some hemostasis parameters in children with acute leukemia after chemotherapy

Abstract

Aim. To improve treatment outcomes of children with acute leukemia after chemotherapy.Materials and Methods. Eighty-five children with AL who were treated at the Department of Pediatric Hematology of the National Medical Center of Tajikistan “Shifobakhsh” and the Regional Cancer Center of Bokhtar during the period 2015-2019 were studied. The study group included 32 children diagnosed with AML and 53 with ALL.All children underwent a comprehensive examination including clinical, X-ray and endoscopic, laboratory tests, ultrasound, CT scan, sternal puncture, and analysis of cerebrospinal fluid.Results and discussion. On admission to the hospital, all hospitalized children had a complete clinical and laboratory picture of AL.We studied 2 groups of patients with AL who received KIT by two schemes. Group 1 - patients with AL received standard therapy. Group 2 - patients with AL, in addition to the standard regimen, received reamberine in combination with remaxol. These medications can protect patients with AL from the toxicity of chemotherapeutic agents used for the treatment of AL, at the same time they don’t decrease the antitumor action of chemotherapeutic agents.Conclusions.1. A marked impairment of hemostasis in children with AL compared to healthy children is observed.2. Conducting KIT in children in combination reamberine with remaxol is more effective compared to standard therapy, as markers of intoxication are significantly reduced.